NextCure (NXTC) Profit After Tax (2018 - 2026)
NextCure (NXTC) posted quarterly Profit After Tax of -$9.8 million for Q1 2026, up 10.54% year-over-year from -$8.9 million in Q1 2025, and down 3.92% quarter-over-quarter from -$9.4 million in Q4 2025.
NextCure (NXTC) Profit After Tax (2018 - 2026) Analysis & Trends
NextCure's Profit After Tax history runs 9 years deep, the most recent figure standing at -$9.8 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 10.54% year-over-year to -$9.8 million; the TTM figure through Mar 2026 stood at -$54.7 million (down 10.82% YoY), while the FY2025 annual figure was -$55.8 million, changed 0.34% from the prior year.
- Profit After Tax for Q1 2026 stood at -$9.8 million, down from -$9.4 million in the prior quarter.
- The five-year high for Profit After Tax was -$8.6 million in Q3 2025, with the low at -$26.8 million in Q2 2025.
- The 5-year median for Profit After Tax is -$15.4 million (2024), against an average of -$15.2 million.
- Peak annual rise in Profit After Tax reached 35.84% in 2025, while the deepest fall reached 74.03% in 2025.
- NextCure's Profit After Tax stood at -$18.1 million in 2022, then gained by 27.22% to -$13.2 million in 2023, then grew by 12.07% to -$11.6 million in 2024, then increased by 18.56% to -$9.4 million in 2025, then fell by 3.92% to -$9.8 million in 2026.
- Business Quant data shows NXTC's Profit After Tax at -$9.8 million in Q1 2026, -$9.4 million in Q4 2025, and -$8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | -14.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.89 Mn |
| Mar 31, 2026 | -9.82 Mn |
| Dec 31, 2025 | -9.45 Mn |
| Sep 30, 2025 | -8.62 Mn |
| Jun 30, 2025 | -26.81 Mn |
| Mar 31, 2025 | -10.98 Mn |
| Dec 31, 2024 | -11.60 Mn |
| Sep 30, 2024 | -11.38 Mn |
| Jun 30, 2024 | -15.40 Mn |
| Mar 31, 2024 | -17.11 Mn |
| Dec 31, 2023 | -13.20 Mn |
| Sep 30, 2023 | -14.30 Mn |
| Jun 30, 2023 | -17.86 Mn |
| Mar 31, 2023 | -16.10 Mn |
| Dec 31, 2022 | -18.13 Mn |
| Sep 30, 2022 | -18.91 Mn |
| Jun 30, 2022 | -17.92 Mn |
| Mar 31, 2022 | -20.60 Mn |
| Dec 31, 2021 | -16.03 Mn |
| Sep 30, 2021 | -17.86 Mn |